Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

Shasqi

Status and phase: Terminated; Phase 2; Phase 1

Conditions: Cancer

Treatments: Drug: SQ3370

Study type: Interventional

Funder types: Industry

Identifiers

NCT04106492

2020-0185 (Other Identifier)

SQ3370-001

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.

Enrollment: 53 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Phase 1: Inclusion Criteria:

1. Diagnosis of advanced soft tissue sarcoma or other solid tumors
2. Adequate hematologic, hepatic, renal, and coagulation function
3. ECOG performance status score 0-1
4. Tumor is the type where published clinical data would suggest that anthracyclines have cytotoxic activity
5. Injectable tumor present

Phase 1: Exclusion Criteria:

1. Prior exposure to 300 mg/m^2 of Dox HCl or DOXIL / CAELYX ® or 600 mg/m^2 of Epirubicin HCl

2. Congestive heart failure (CHF), severe myocardial insufficiency, or cardiac arrhythmia

3. Any of the following within 28 days prior to Cycle 1 Day 1:

   • Major surgery, as defined by the Investigator
   • Radiotherapy
   • Chemotherapy, immunotherapy and/or anticancer therapy (except for small molecule kinase inhibitors, which are 6 elimination half-lives)

4. Trastuzumab or trastuzumab emtansine dosed within 7 months prior to Cycle 1 Day 1.

5. Any transfusion within 14 days prior to Cycle 1 Day 1.

6. Pregnant or breast-feeding women.

7. Known active CNS metastases and/or carcinomatous meningitis or symptomatic brain metastasis. Participants with previously treated brain metastases may participate provided they are radiologically stable

8. History of allergic reactions attributed to Dox or other anthracyclines, NaHA, hyaluronic acid, or gram-positive bacterial proteins

9. History or evidence of clinically unstable/uncontrolled disorder, condition, or disease

Phase 2a Expansion Group 1 (Extremity STS): Inclusion

1. Patients with unresectable soft tissue sarcomas of the extremity AJCC Stage III OR select IV (=>5 cm injectable tumors) locally advanced and or metastatic, not amendable to primary surgical intervention according to the consensus of a multidisciplinary treatment team, determined prior to screening.
2. High grade STS, Grade 2/3, with an assessable/injectable lesion of at least diameter ≥5 cm by RECIST 1.1 criteria
3. No prior chemotherapy for STS, or radiation to affected limb

Phase 2a Expansion Group 1 (Extremity STS): Exclusion

1. Uncontrolled pain related to tumor
2. Open wounds or tissue necrosis related to tumor mass
3. Compartment syndrome or impending compartment syndrome

Phase 2a Expansion Group 2 (Unresectable STS): Inclusion

1. Locally advanced or metastatic, unresectable, soft-tissue sarcoma of intermediate or high grade with measurable disease.
2. Life expectancy >12 weeks (about 3 month)

Phase 2a Expansion Group 2 (Unresectable STS): Exclusion

1. Prior exposure to anthracyclines
2. Treatment naive extremity tumors

Phase 2a Expansion Group 3a (Head and Neck): Inclusion

1. Patients with histologically or cytologically confirmed squamous-cell carcinoma of the head and neck (HNSCC) who meet any of the following a) confirmed relapsed HNSCC or b) metastatic at initial presentation HNSCC
2. Patients who may have received two or less systemic regimens (therapies include chemotherapy and/or immunotherapy)

Phase 2a Expansion Group 3a (Head and Neck): Exclusion

1. Airway obstruction by tumor mass that requires clinical intervention
2. Prior treatment with anthracyclines

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

53 participants in 15 patient groups

Dose Escalation Cohort 1 (10 mL SQL70 and 8 mg/m^2 of SQP33)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 8 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors

Treatment:

Drug: SQ3370

Dose Escalation Cohort 2 (10 mL SQL70 and 16 mg/m^2 of SQP33)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 16 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors.

Treatment:

Drug: SQ3370

Dose Escalation Cohort 3 (10 mL SQL70 and 32 mg/m^2 of SQP33)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 32 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors.

Treatment:

Drug: SQ3370

Dose Escalation Cohort 4 (10 mL SQL70 and 58 mg/m^2 of SQP33)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 58 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors.

Treatment:

Drug: SQ3370

Dose Escalation Cohort 5 (10 mL SQL70 and 85 mg/m^2 of SQP33)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 85 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors

Treatment:

Drug: SQ3370

Dose Escalation Cohort 6 (10 mL SQL70 and 125 mg/m^2 of SQP33)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 125 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors

Treatment:

Drug: SQ3370

Dose Escalation Cohort 7 (10 mL SQL70 and 185 mg/m^2 of SQP33)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 185 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors

Treatment:

Drug: SQ3370

Dose Escalation Cohort 8 (10 mL SQL70 and 250 mg/m^2 of SQP33)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 250 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors

Treatment:

Drug: SQ3370

Dose Escalation Cohort 9 (10 mL SQL70 and 315 mg/m^2 of SQP33)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 315 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors

Treatment:

Drug: SQ3370

Dose Escalation Cohort (20 mL SQL70 and 85 mg/m^2 of SQP33)

Experimental group

Description:

20 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 85 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors

Treatment:

Drug: SQ3370

Dose Escalation Cohort (20 mL SQL70 and 125 mg/m^2 of SQP33)

Experimental group

Description:

20 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 125 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors

Treatment:

Drug: SQ3370

Cohort A (10 mL SQL70 and 185 mg/m^2 of SQP33)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 185 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors

Treatment:

Drug: SQ3370

P2a Group 1 (Extremity STS) (20 mL SQL70 and 250 mg/m^2/Day of SQP33)

Experimental group

Description:

20 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 250 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with soft tissue sarcomas of the extremity

Treatment:

Drug: SQ3370

P2a Group 2 (10 mL SQL70 and 500 mg/m^2/ of SQP33 for 2 days and and 250 mg/m^2/ of SQP33 for 1 day)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 500 mg/m\^2 of SQP33 infused on Day 1 and 2 with 250 mg/m\^2 of SQP33 infused on each Day 3 in subjects with locally advanced, unresectable or metastatic soft tissue sarcomas who are anthracycline naïve

Treatment:

Drug: SQ3370

P2a Group 2 (10 mL SQL70 and 250 mg/m^2/day of SQP33 for five days)

Experimental group

Description:

10 mL of SQL70 injected intratumorally on Day with 250 mg/m\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced, unresectable or metastatic soft tissue sarcomas who are anthracycline naïve

Treatment:

Drug: SQ3370